Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer

被引：32

作者：

Chua, Wei ^{[2
]}

Kho, Patricia S. ^{[2
]}

Moore, Melissa M. ^{[2
]}

Charles, Kellie A. ^{[3
,4
]}

Clarke, Stephen J. ^{[1
,2
]}

机构：

[1] Concord Repatriat Gen Hosp, Sydney Canc Ctr, Dept Med, Concord, NSW 2139, Australia

[2] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia

[3] Univ Sydney, Sch Med Sci Pharmacol, Sydney, NSW 2006, Australia

[4] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2011年 / 79卷 / 03期

关键词：

Colorectal cancer; Chemotherapy; Monoclonal antibodies; Predictive factor; Biomarker; GROWTH-FACTOR-RECEPTOR; THYMIDYLATE-SYNTHASE GENE; THYMIDINE PHOSPHORYLASE EXPRESSION; FLUOROURACIL-BASED CHEMOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP; CETUXIMAB PLUS IRINOTECAN; III COLON-CANCER; DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY; TUMOR MICROSATELLITE-INSTABILITY; SINGLE NUCLEOTIDE POLYMORPHISMS;

D O I：

10.1016/j.critrevonc.2010.07.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Colorectal cancer (CRC) treatment has evolved significantly over the last ten years with the use of active chemotherapeutic agents including fluoropyrimidines, oxaliplatin and irinotecan plus targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab. The addition of newer chemotherapeutic agents and targeted therapies has improved patient outcomes at the cost of increased toxicity with not all patients benefiting from these treatments. It is necessary for clinicians to more accurately predict clinical outcomes particularly in the predominantly elderly CRC patient population. This review aims to summarise existing data regarding the use of clinical and laboratory variables plus molecular markers in predicting response, survival and toxicity to chemotherapy agents and targeted monoclonal antibodies currently used in the treatment of CRC. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：224 / 250

页数：27

共 240 条

[1]

Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group [J].

Albain, Kathy S. ;

Unger, Joseph M. ;

Crowley, John J. ;

Coltman, Charles A., Jr. ;

Hershman, Dawn L. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (14) :984-992

[2]

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[3]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[4]

Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[5]

[Anonymous], NCCN CLIN PRACT GUID

[6]

[Anonymous], J CLIN ONCOL S

[7]

Microsatellite instability and colorectal cancer prognosis [J].

Benatti, P ;

Gafà, R ;

Barana, D ;

Marino, M ;

Scarselli, A ;

Pedroni, M ;

Maestri, I ;

Guerzoni, L ;

Roncucci, L ;

Menigatti, M ;

Roncari, B ;

Maffei, S ;

Rossi, G ;

Ponti, G ;

Santini, A ;

Losi, L ;

Di Gregorio, C ;

Oliani, C ;

de Leon, MP ;

Lanza, G .

CLINICAL CANCER RESEARCH, 2005, 11 (23) :8332-8340

[8]

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[9]

When does the presence of the target predict response to the targeted agent? [J].

Bergsland, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) :213-216

[10]

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 [J].

Bertagnolli, Monica M. ;

Niedzwiecki, Donna ;

Compton, Carolyn C. ;

Hahn, Hejin P. ;

Hall, Margaret ;

Damas, Beatrice ;

Jewell, Scott D. ;

Mayer, Robert J. ;

Goldberg, Richard M. ;

Saltz, Leonard B. ;

Warren, Robert S. ;

Redston, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1814-1821

← 1 2 3 4 5 6 7 8 9 10 →